Section
A biodegradable PLGA microsphere–thermo‑responsive hydrogel delivering aflibercept was well tolerated after single intravitreal injection in 23 rhesus macaques with preserved retinal structure and function up to 24 months.
A prospective phase IV open‑label Chinese study found cenegermin achieved corneal healing in 84.6% of stage 2/3 neurotrophic keratopathy patients at 8 weeks, with durable effects through 56 weeks and an acceptable safety profile.
This cohort study tracks diabetic retinopathy incidence over 24 years in type 2 diabetes patients, highlighting the impact of glycemic control and hypertension on disease progression.
GLP-1 receptor agonists used in diabetes show a twofold increased risk of neovascular AMD, a modest risk elevation for diabetic retinopathy, and a small but significant increased risk for nonarteritic anterior ischemic optic neuropathy, war
A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudat
Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.
This analysis highlights how intensive multifactorial management and glycemic control influence diabetic retinopathy onset, emphasizing the risks associated with hypoglycemia despite good glycemic control.
THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis ben
This review synthesizes current evidence from large cohorts, meta-analyses, and randomized trials evaluating metformin’s association with AMD development and progression, highlighting a nuanced but inconclusive protective potential re
The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.
A 38-year-old male with bilateral blurred vision and neurological symptoms was diagnosed with Vogt-Koyanagi-Harada syndrome and managed successfully with corticosteroids and immunosuppressants.
This study reveals that socioeconomic status, residential location, and household composition significantly affect treatment outcomes and follow-up in newly diagnosed POAG patients, highlighting the need for targeted strategies to improve g
This review synthesizes evidence on the incidence of acute angle closure (AAC) following pharmacologic pupillary dilation in a large teleretinal screening program, confirming the very low risk and supporting dilation safety in diverse popul
A UK study reveals most patients with geographic atrophy are open to intravitreal complement inhibitor injections if these treatments offer vision improvement, highlighting the vital role of functional benefits in therapy acceptance.
This study compares atropine and cyclopentolate for cycloplegia in preschoolers, finding atropine leads to less myopic refraction and may reduce premyopia overestimation. It highlights implications for precise refractive diagnosis in young
A recent randomized, double-blind trial demonstrates that oral lamivudine significantly improves visual acuity in patients with center-involved diabetic macular edema, offering a cost-effective and safer alternative to conventional anti-VEG
A novel deep learning model predicted retinal nerve fiber layer thickness from optic disc photos, enabling risk stratification for primary open-angle glaucoma in ocular hypertension patients, with baseline and longitudinal changes strongly
Deep learning models predicting RNFL thickness from optic disc photographs can identify ocular hypertension patients at higher risk for primary open-angle glaucoma, enhancing early risk assessment and monitoring disease progression.
A recent randomized clinical trial demonstrates that diversified segmental defocus optimization (DSDO) spectacle lenses significantly reduce the onset and progression of myopia in children, with or without adjunct low-dose atropine.
Low-level light therapy, administered perioperatively, significantly reduces dry eye symptoms and preserves ocular surface integrity after cataract surgery, offering a noninvasive adjunct to standard care.
